TABLE 1.
SBA geometric mean antibody titers (GMT) against serogroup B before and after immunization with meningococcal vaccinea
| Study time point | No. of subjects in indicated group; GMT (95% CI)
|
||
|---|---|---|---|
| MenB/C | MenB | MenC | |
| Prestudy | 32; 4.8 (2.9-7.9) | 15; 2.9 (1.4-6.1) | 19; 3.1 (1.9-5.2) |
| 6 weeks after 1st dose | 32; 10.8 (6.3-18.5) | 15; 8.8 (4.0-19.2) | 19; 3.1 (1.8-5.2) |
| 6 weeks after 2nd dose | 30; 14.6 (8.9-23.9) | 15; 10.6 (5.2-21.2) | 19; 2.4 (1.5-3.7) |
| 6 weeks after 3rd dose | 29; 29.1 (17.3-49.0) | 14; 14.5 (6.8-30.7) | 19; 2.2 (1.4-3.2) |
| 1 year after 1st dose | 27; 16.4 (9.8-27.5) | 15; 7.3 (3.6-14.6) | 17; 4.2 (2.8-6.1) |
a
Subjects in the MenB/C group received one dose of MenB/C followed by two doses of MenBvac, subjects in the MenB group received three doses of MenBvac, and subjects in the MenC group received one dose of Menjugate followed by two doses of placebo (aluminum hydroxide).